[go: up one dir, main page]

WO2018132639A8 - Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid - Google Patents

Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid Download PDF

Info

Publication number
WO2018132639A8
WO2018132639A8 PCT/US2018/013453 US2018013453W WO2018132639A8 WO 2018132639 A8 WO2018132639 A8 WO 2018132639A8 US 2018013453 W US2018013453 W US 2018013453W WO 2018132639 A8 WO2018132639 A8 WO 2018132639A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
kits
ocp
prognosis
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/013453
Other languages
French (fr)
Other versions
WO2018132639A1 (en
Inventor
Charles Stephen FOSTER
Razzaque AHMED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018132639A1 publication Critical patent/WO2018132639A1/en
Publication of WO2018132639A8 publication Critical patent/WO2018132639A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides methods of diagnosing ocular cicatricial pemphigoid (OCP) in a subject, by determining the level or concentration of autoantibodies that bind β4 integrin in a biological sample obtained from the subject. In embodiments, the concentration of anti-β4 integrin autoantibodies is determined using an ELISA. Methods of monitoring the course of OCP, methods of treating OCP, and kits for diagnosing OCP are also provided.
PCT/US2018/013453 2017-01-13 2018-01-12 Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid Ceased WO2018132639A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762446080P 2017-01-13 2017-01-13
US62/446,080 2017-01-13

Publications (2)

Publication Number Publication Date
WO2018132639A1 WO2018132639A1 (en) 2018-07-19
WO2018132639A8 true WO2018132639A8 (en) 2019-06-27

Family

ID=61226655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/013453 Ceased WO2018132639A1 (en) 2017-01-13 2018-01-12 Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid

Country Status (1)

Country Link
WO (1) WO2018132639A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115508554A (en) * 2022-10-13 2022-12-23 大连大学 A diagnostic kit for mucosal pemphigoid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
WO1994021822A1 (en) 1993-03-19 1994-09-29 Sequenom, Inc. Dna sequencing by mass spectrometry via exonuclease degradation
WO2011160096A2 (en) * 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition

Also Published As

Publication number Publication date
WO2018132639A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
WO2017070114A3 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
HK1205764A1 (en) Tuberculosis biomarkers and uses thereof
JP2017524130A5 (en)
TN2017000502A1 (en) Methods of diagnosing and treating cancer
MX350533B (en) Pancreatic cancer biomarkers and uses thereof.
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
MX2017003370A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm.
EP4299586A3 (en) Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
BR112022011676A2 (en) KIT TO DETECT AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES, METHOD TO DETECT AND/OR QUANTIFY IT AND CARTRIDGE TO PERFORM SUCH METHOD
ATE370414T1 (en) USE OF NICOTINAMIDE N-METHYLTRANSFERASE FOR DIAGNOSING COLORECTAL CANCER
HK1232238A1 (en) Novel assay to detect human periostin
EP4220171A3 (en) Markers for endometrial cancer
EP3178846A3 (en) Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
ZA202106673B (en) Salivary biomarkers of brain injury
WO2015166353A3 (en) Early detection of preeclampsia
WO2015197915A3 (en) Biochemical markers for use in determining risk of diabetes
EP3502271A3 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers
WO2018132639A8 (en) Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid
MX2021003484A (en) Methods for detecting hook effect(s) associated with anaylte(s) of interest during or resulting from the conductance of diagnostic assay(s).
WO2011063389A3 (en) Normalization of platelet biomarkers
WO2021138273A3 (en) Autoantibodies as biomarkers for autoimmune polyglandular syndrome type 1
EP3599288A3 (en) Diagnosis and treatment of psoriatic arthritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18705514

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18705514

Country of ref document: EP

Kind code of ref document: A1